Jennifer Lew Buys Shares of Boundless Bio, Inc. $BOLD
Key Points
- Jennifer Lew bought 32,000 shares of Boundless Bio, Inc. ($BOLD).
- $BOLD last traded around $1.40.
Jennifer Lew, insider at Boundless Bio, Inc. ($BOLD), bought 32,000 shares at an average price of $0.00. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Boundless Bio, Inc. ($BOLD) Stock
Boundless Bio, Inc. Earnings
Analysts Set New Price Targets
About Boundless Bio, Inc.
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.